Literature DB >> 17461472

Abdominal computed tomography in refractory coeliac disease and enteropathy associated T-cell lymphoma.

Maarten Mallant1, Muhammed Hadithi, Abdul-Baqi Al-Toma, Matthijs Kater, Maarten Jacobs, Radu Manoliu, Chris Mulder, Jan-Hein van Waesberghe.   

Abstract

AIM: To evaluate computed tomography (CT) findings, useful to suggest the presence of refractory celiac disease (RCD) and enteropathy associated T cell lymphoma (EATL).
METHODS: Coeliac disease (CD) patients were divided into two groups. Group I: uncomplicated CD (n = 14) and RCD type I (n = 10). Group II: RCD type II (n = 15) and EATL (n = 7).
RESULTS: Both groups showed classic signs of CD on CT. Intussusception was seen in 1 patient in group I vs 5 in group II (P = 0.06). Lymphadenopathy was seen in 5 patients in group II vs no patients in group I (P = 0.01). Increased number of small mesenteric vessels was noted in 20 patients in group I vs 11 in group II (P = 0.02). Eleven patients (50%) in group II had a splenic volume < 122 cm3 vs 4 in group I (14%), 10 patients in group I had a splenic volume > 196 cm3 (66.7%) vs 5 in group II (33.3%) P = 0.028.
CONCLUSION: CT scan is a useful tool in discriminating between CD and (Pre) EATL. RCD II and EATL showed more bowel wall thickening, lymphadenopathy and intussusception, less increase in number of small mesenteric vessels and a smaller splenic volume compared with CD and RCD I.

Entities:  

Mesh:

Year:  2007        PMID: 17461472      PMCID: PMC4146948          DOI: 10.3748/wjg.v13.i11.1696

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  28 in total

1.  Adult celiac disease: US signs.

Authors:  T Rettenbacher; A Hollerweger; P Macheiner; S Huber; N Gritzmann
Journal:  Radiology       Date:  1999-05       Impact factor: 11.105

Review 2.  Coeliac disease.

Authors:  S Martucci; F Biagi; A Di Sabatino; G R Corazza
Journal:  Dig Liver Dis       Date:  2002-09       Impact factor: 4.088

3.  CT findings of increased splanchnic circulation in a case of celiac sprue.

Authors:  P P Moser; J K Smith
Journal:  Abdom Imaging       Date:  2004 Jan-Feb

4.  Jejunal fold separation in adult celiac disease: relevance of enteroclysis.

Authors:  H Herlinger; D D Maglinte
Journal:  Radiology       Date:  1986-03       Impact factor: 11.105

5.  Adaptation of the ileum in nontropical sprue: reversal of the jejunoileal fold pattern.

Authors:  J G Bova; A C Friedman; E Weser; T A Hopens; D H Wytock
Journal:  AJR Am J Roentgenol       Date:  1985-02       Impact factor: 3.959

6.  Effect of gluten-free diet on splenic hypofunction of adult coeliac disease.

Authors:  G R Corazza; M Frisoni; D Vaira; G Gasbarrini
Journal:  Gut       Date:  1983-03       Impact factor: 23.059

7.  Splenic size and function in adult coeliac disease.

Authors:  P J Robinson; A W Bullen; R Hall; R C Brown; P Baxter; M S Losowsky
Journal:  Br J Radiol       Date:  1980-06       Impact factor: 3.039

8.  Small bowel malignant lymphoma complicating celiac sprue and the mesenteric lymph node cavitation syndrome.

Authors:  H J Freeman; B K Chiu
Journal:  Gastroenterology       Date:  1986-06       Impact factor: 22.682

9.  Azathioprine and prednisone combination therapy in refractory coeliac disease.

Authors:  M S Goerres; J W R Meijer; P J Wahab; J A M Kerckhaert; P J T A Groenen; J H J M Van Krieken; C J J Mulder
Journal:  Aliment Pharmacol Ther       Date:  2003-09-01       Impact factor: 8.171

10.  Celiac disease: does hyposplenism predispose to the development of malignant disease?

Authors:  J G O'Grady; F M Stevens; C F McCarthy
Journal:  Am J Gastroenterol       Date:  1985-01       Impact factor: 10.864

View more
  9 in total

1.  Evaluation of Cladribine treatment in refractory celiac disease type II.

Authors:  Greetje J Tack; Wieke H M Verbeek; Abdul Al-Toma; Dirk J Kuik; Marco W J Schreurs; Otto Visser; Chris J J Mulder
Journal:  World J Gastroenterol       Date:  2011-01-28       Impact factor: 5.742

Review 2.  Classification and management of refractory coeliac disease.

Authors:  Alberto Rubio-Tapia; Joseph A Murray
Journal:  Gut       Date:  2010-04       Impact factor: 23.059

Review 3.  Enteropathy-associated T-cell lymphoma: epidemiology, clinical features, and current treatment strategies.

Authors:  Michal K Sieniawski; Anne L Lennard
Journal:  Curr Hematol Malig Rep       Date:  2011-12       Impact factor: 3.952

4.  Splenic volume differentiates complicated and non-complicated celiac disease.

Authors:  Tom van Gils; Petula Nijeboer; Jan Hein Tm van Waesberghe; Veerle Mh Coupé; Kiki Janssen; Jessy A Zegers; Shaikh A Nurmohamed; Georg Kraal; Sabine Ci Jiskoot; Gerd Bouma; Chris Jj Mulder
Journal:  United European Gastroenterol J       Date:  2016-08-17       Impact factor: 4.623

Review 5.  Mechanisms and management of refractory coeliac disease.

Authors:  Tom van Gils; Petula Nijeboer; Roy L van Wanrooij; Gerd Bouma; Chris J J Mulder
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-09-08       Impact factor: 46.802

6.  Association of intussusception and celiac disease in adults.

Authors:  Tamas A Gonda; Sharif-Uz-Zaman Khan; Jian Cheng; Suzanne K Lewis; Moshe Rubin; Peter H R Green
Journal:  Dig Dis Sci       Date:  2009-12-24       Impact factor: 3.199

7.  Fatal Streptococcus pneumoniae Sepsis in a Patient With Celiac Disease-Associated Hyposplenism.

Authors:  Madhu M Ouseph; Malorie Simons; Diana O Treaba; Evgeny Yakirevich; Peter H Green; Govind Bhagat; Steven F Moss; Shamlal Mangray
Journal:  ACG Case Rep J       Date:  2016-10-12

8.  Update on the diagnosis and management of refractory coeliac disease.

Authors:  Petula Nijeboer; Roy L J van Wanrooij; Greetje J Tack; Chris J J Mulder; Gerd Bouma
Journal:  Gastroenterol Res Pract       Date:  2013-05-09       Impact factor: 2.260

Review 9.  Non-Responsive Coeliac Disease: A Comprehensive Review from the NHS England National Centre for Refractory Coeliac Disease.

Authors:  Hugo A Penny; Elisabeth M R Baggus; Anupam Rej; John A Snowden; David S Sanders
Journal:  Nutrients       Date:  2020-01-14       Impact factor: 5.717

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.